Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib vs Chlorambucil + Rituximab in Untreated CLL
NCT04075292Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2020
- Primary completion
- Jan 2024
- Countries
- 5
01
Overview
A Phase 3 trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), sponsored by AstraZeneca. Started Jan 2020; status: active, not recruiting.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT04075292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04075292.